humanitarian
Archived signal
Human medicines European public assessment report (EPAR): Denbrayce, denosumab, Date of authorisation: 26/06/2025, Revision: 3, Status: Authorised
Human medicines European public assessment report (EPAR): Zumrad, sasanlimab, Status: Application withdrawn
Reported by EMA What Is New
Read the complete report at EMA What Is New ↗
Verification notice
IntelMap indexes open-source reporting. This page identifies what a source reported; it does not independently confirm the claim.
6 reports · 2 sources
EMA What Is NewHuman medicines European public assessment report (EPAR): Denbrayce, denosumab, Date of authorisation: 26/06/2025, Revision: 3, Status: AuthorisedEMA What Is NewHuman medicines European public assessment report (EPAR): Denbrayce, denosumab, Date of authorisation: 26/06/2025, Revision: 3, Status: AuthorisedEMA What Is NewHuman medicines European public assessment report (EPAR): Paxneury, guanfacine, Date of authorisation: 26/02/2025, Revision: 2, Status: AuthorisedEMA What Is NewHuman medicines European public assessment report (EPAR): Paxneury, guanfacine, Date of authorisation: 26/02/2025, Revision: 2, Status: AuthorisedEMA What Is NewHuman medicines European public assessment report (EPAR): Qinlock, ripretinib, Date of authorisation: 18/11/2021, Revision: 11, Status: AuthorisedEMA What Is NewHuman medicines European public assessment report (EPAR): Qinlock, ripretinib, Date of authorisation: 18/11/2021, Revision: 11, Status: Authorised4 recorded states
Signal first indexedP2 · 99% quality · 2 sources
Source details updatedP2 · 99% quality · 2 sources
Headline updatedP2 · 99% quality · 2 sources
Source details updatedP2 · 99% quality · 2 sources